Diabetes drug may protect against cancer

Yesterday, I covered some of the key pathways and kinases associated with cell energy metabolism, LKB1 and AMPK.  These, together with Insulin-like Growth Factor-I (IGF-I) and the insulin receptor (IR), appear to play important roles in the broader regulation of energy and homeostasis.  Experimental evidence suggests that an overexpression of IGF-I is implicated in pancreatic tumours, for example. Increased IGF-II and decreased IGF binding protein (IGFBP)-3 serum concentrations have also been linked to a number of other cancers.

If we look at the IGF-IR pathway, we can see more clearly how they all interlink and how mTOR, LKB1 and AMPK may all be a critical part of the process:

0 responses on "Diabetes drug may protect against cancer"

Leave a Message

Your email address will not be published. Required fields are marked *


Join fastest growing subscribers who benefit from PharmaCrunch’s coverage on "Pharmaceuticals - Must to Know" updates

Testimonial from Subscribers

Read more

Nirbhay Patel

Business Manager - Sanofi India
2016 © PharmaCrunch All rights reserved
Skip to toolbar